WHO Report: MDR and XDR-TB to 2015

WHO issued a progress report Towards universal access to diagnosis and treatment of MDR and XDR-TB by 2015 noting “progress is being made, but the response is far from sufficient given the MDR-TB threat facing the world. Two years on from the Beijing declaration – which was endorsed by all 27 high burden countries featured in this report – the commitments by some countries are too slow off the mark or simply stalled.” In relation to the 27 high burden MDR-TB countries, WHO reported:

– Funding: MDR-TB action plans exist in most of the 27 countries. Funding has increased, from $0.1b in 2009, to $0.5 billion in 2011. However, the estimated need in the Global Plan for MDR-TB worldwide in 2011 is $0.9b.

– Labs: Capacity has increased, but is still only adequate in 60% of the countries.

– Treatment: Only one-in-ten MDR-TB patients have access to treatment – and cure rates range widely from 25% to 82%.

– Drugs: The Global Drug Facility has more than doubled the number of finished pharmaceutical products for MDR-TB from 11 in 2008 to 25 today.

– Treatment capacity: If diagnostic capacity increases substantially in the next few months, the availability of second line drugs to treat all those diagnosed will be a challenge.

– TB infection control: In many countries this is still at a planning stage.

– Surveillance: Major progress has been made. By mid 2012, all 27 countries will have representative information on drug resistance.

MDR and XDR-TB progress report 2011 – fact sheet
MDR and XDR-TB: WHO progress report 2011

World TB Day, 24 March 2011 – NIH Statement

World TB Day, 24 March 2011, Statement of Christine F. Sizemore, Ph.D., and Anthony S. Fauci, M.D., National Institute of Allergy and Infectious Diseases
National Institutes of Health.

[Excerpt]
“…Recent developments have created confidence that TB control strategies can be improved to stay abreast of the changing nature of the pandemic. For the first time in decades, a robust pipeline of candidate TB drugs, vaccines, diagnostics, and treatment and prevention strategies are being evaluated in clinical trials. WHO recently endorsed a diagnostic test that enables health care providers to identify drug-resistant TB directly from patient specimens within about two hours rather than waiting months for a conclusive diagnosis. Drugs are being developed that, when combined in novel ways, may significantly improve the way we treat patients with TB. Vaccines are being developed that may one day prevent the disease, even in persons who are already infected with Mtb….”

Full statement at: http://www.nih.gov/news/health/mar2011/niaid-21.htm

FDA approves Zostavax (zoster) for adults 50 – 59

The Food and Drug Administration (FDA) approved the use of Zostavax, a live attenuated virus vaccine, for the prevention of shingles in individuals 50 to 59 years of age. Zostavax is already approved for use in individuals 60 years of age and older. Karen Midthun, M.D., director of FDA’s Center for Biologics Evaluation and Research, commented, “The likelihood of shingles increases with age. The availability of Zostavax to a younger age group provides an additional opportunity to prevent this often painful and debilitating disease.” The FDA noted that approval “was based on a multicenter study conducted in the United States and four other countries in approximately 22,000 people who were 50-59 years of age. Half received Zostavax and half received a placebo. Study participants were then monitored for at least one year to see if they developed shingles. Compared with placebo, Zostavax reduced the risk of developing shingles by approximately 70 percent.”

http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm248390.htm

Report: The Abuja Declaration – Ten Years On

The WHO announced a new report – The Abuja Declaration: Ten Years On. The report abstract notes: “In April 2001, heads of state of African Union countries met in Abuja, Nigeria and pledged to set a target of allocating at least 15% of their annual budget to improve the health sector. At the same time, they urged donor countries to “fulfil the yet to be met target of 0.7% of their GNP as official Development Assistance (ODA) to developing countries”. This drew attention to the shortage of resources necessary to improve health in low income settings.

“Only two African countries have reached that target. Overall, 27 have increased the proportion of government expenditures allocated to health and seven have reduced it since 2001. In the other 12, there is no obvious trend up or down. Current donor spending varies dramatically, from US$ 115 per person in one country, to less than US$ 5 per person in 12 others.”

http://www.who.int/healthsystems/publications/abuja_declaration/en/index.html

Four page summary report at: http://www.who.int/entity/healthsystems/publications/abuja_10.pdf

Meeting: CEWG – Consultative Expert Working Group on Research and Development

The WHO posted an invitation to attend the Open Sessions of the first meeting of the Consultative Expert Working Group on Research and Development: financing and coordination (CEWG):

Place: WHO Executive Room, Geneva Switzerland
Date: 5-7 April 2011

“Members of the CEWG will meet to take forward the work of its predecessor, the Expert Working Group (EWG). They will deepen the analysis of the proposals considered by the EWG and consider further proposals for financing and coordination of research and development for diseases that disproportionally affect developing countries. To ensure transparency in the work of the CEWG, Member States and other stakeholders may attend the open sessions of the meeting. In particular Member States and other stakeholders may attend the following sessions subject to registration.

– Open Session on 5th April 2011, Tuesday, 9.30am to 3.30pm

– Open Forum on 6th April 2011, Wednesday, 9am to 6pm

– Open Session on 7th April 2011, Thursday, 5.30pm to 6pm

http://www.who.int/mediacentre/events/meetings/2011/cewg/en/index.html

World Vaccines Market and Future Forecast

[Editor’s Note: We do not endorse the findings of or have any business relationships with market research firms which analyze the vaccines marketplace. But we do monitor new research and occasionally provide highlight, especially when such research provides insights into the scale or dynamics of the vaccines marketplace]

World Vaccines Market: Vaccine Segments Analysis, Vaccine Cases and Future Forecast

“…As growth in sales of vaccines has become higher than the traditional business all major pharmaceutical companies are eyeing the vaccine market as driver for their growth. Many mergers and acquisition have taken place in this space as consolidation has become the keyword for future growth. With companies consolidating they can focus better in the market and keep their profit margins high. Recently, pharmaceutical company Pfizer acquired Wyeth, Merck acquired Schering Plough and Sanofi acquired Shantha Biotechnics….”
“…Due to rising fear of terrorism Bio- Bio-protection vaccine future is also shinning. The Bio-protection vaccines market is expected to grow with a CAGR of 12.08% percent from 2009 to 2015…Seasonal flu vaccine market is forecasted to be more than US$ 7 billion by 2016…”

Research Highlights [selected]:
– World vaccines market will cross the mark of US$40 Billion by 2015
– Pediatric proprietary vaccine market is the biggest vaccine sector with more than US$6 Billion market in 2009
– In 2009 four companies (GSK, Sanofi-Aventis, Wyeth and Merck & Co.) together control 71% of the vaccines market worldwide
– Influenza vaccine market is expected to cross US$ 7 Billion market by 2015
– Bio-protection and Travel & Endemic vaccines market is expected to double by 2015 from their market in 2009
– US is the biggest vaccine market worldwide with more than US$10 Billion and its expected to lead the market till 2015

– Malaria vaccine market for public is expected to cross US$400 Million by 2025
– Cervical Cancer vaccine market is forecasted to cross US$4 Billion mark by 2012 and thereafter its year on year growth will slow down
– Prevner a Pfizer a product is expected to become the first vaccine to cross US$5 Billion mark by 2015
http://www.researchandmarkets.org